Table 3: Univariate analysis of health characteristics factors affecting the development of diabetic nephropathy complication.

 

Health characteristics

ba

Crude OR (95% CIb)

P value

BMI

-0.21

0.80 (0.77,0.84)

< 0.001

WC

-0.07

0.92 (0.90,0.94)

< 0.001

Duration of diabetes 

0.09

1.09 (1.05,1.14)

< 0.001

Macrovascular complications

No

Yes

 

0

1.71

 

1

5.56 (2.02,15.31)

 

-

0.001

Antidiabetic medications

Metformin

 

0

 

1

0.003

-

Gliclazide

1.00

2.72 (0.91,8.09)

0.071

Mixtard insulin

1.75

5.75 (1.24,26.62)

0.025

Metformin + Gliclazide

0.29

1.34 (0.66,2.71)

0.411

Metformin + Mixtard insulin

0.49

1.63 (0.67,3.99)

0.278

Gliclazide + Acarbose

2.15

8.57 (1.08,68.12)

0.042

Metformin + Gliclazide + Rosiglitazone

0.44

0.63 (0.28,1.45)

0.284

Metformin + Gliclazide + Acarbose

0.34

1.40 (0.59,3.30)

0.435

Metformin + Gliclazide + NPH insulin

1.15

3.17 (1.19,8.40)

0.020

Retinopathy

No

Yes

 

0

0.55

 

1

1.74 (1.10,2.75)

 

-

0.016

Neuropathy

No

Yes

 

0

0.81

 

1

2.24 (1.47,3.44)

 

-

< 0.001

 

OR: Odds Ratio; CI: Confidence Interval  

aSimple logistic regression ( outcome as nephropathy complication)

References category: macrovascular complication: no, references category: antidiabetic medication: metformin, references category retinopathy: no, references category neuropathy: no